NovoCure
NVCR
311 hedge funds and large institutions have $5.94B invested in NovoCure in 2021 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 124 increasing their positions, 92 reducing their positions, and 61 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 92
1.3% more ownership
Funds ownership: 74.86% → 76.17% (+1.3%)
5% more call options, than puts
Call options by funds: $124M | Put options by funds: $119M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 61
2% less funds holding
Funds holding: 317 → 311 (-6)
34% less capital invested
Capital invested by funds: $9.02B → $5.94B (-$3.08B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$77.8M |
| 2 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
+$30.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.7M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$24.6M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$47.3M |
| 2 |
DCP
Darsana Capital Partners
New York
|
-$44.3M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$26.8M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$21.3M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$16.9M |
NVCR Hedge Fund Activity: Q4 2021 in Review
311 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2021, worth a combined $5.94B — down 34% from $9.02B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of NVCR and 57 opened new positions — a net loss of 4 holders — while 92 trimmed existing stakes and 124 added.
The largest buyer was Capital International Investors, adding an estimated $77.8M. The largest seller was Fidelity Investments, cutting an estimated $47.3M.
- 311 institutional investors held NovoCure (NVCR) as of Q4 2021, down from 317 in Q3 2021.
- Funds reported $5.94B of NovoCure stock for Q4 2021, down 34% quarter-over-quarter.
- 57 funds opened new NovoCure positions in Q4 2021 and 61 closed out, a net change of -4 holders.
- The largest NovoCure buyer in Q4 2021 was Capital International Investors, an estimated $77.8M added.
- The largest NovoCure seller in Q4 2021 was Fidelity Investments, an estimated $47.3M sold.
Based on aggregated 13F filings for Q4 2021.